Clinical Scorecard: Two-Drug HIV Regimen Gains FDA Approval
At a Glance
Category
Detail
Condition
Virologically suppressed HIV-1 infection
Key Mechanisms
Doravirine inhibits reverse transcriptase; Islatravir is a nucleoside analog interfering with viral replication via multiple mechanisms
Target Population
Adults with HIV-1 RNA <50 copies/mL, no history of treatment failure, and no resistance to doravirine
Care Setting
Outpatient management of stable HIV-1 infection
Key Highlights
FDA approved once-daily oral doravirine/islatravir (DOR/ISL) for virologically suppressed adults with HIV-1
Phase 3 trials demonstrated noninferior efficacy and comparable safety versus standard antiretroviral therapy at 48 and 96 weeks
DOR/ISL is a two-drug, tenofovir-free regimen without integrase strand transfer inhibitors, offering a simplified treatment option
Guideline-Based Recommendations
Diagnosis
Confirm virologic suppression with HIV-1 RNA <50 copies/mL before switching to DOR/ISL
Assess for absence of treatment failure history and doravirine resistance-associated substitutions
Management
Use DOR/ISL as a complete antiretroviral therapy regimen in eligible patients
Avoid co-administration with other antiretrovirals
Do not use with strong CYP3A inducers or with lamivudine/emtricitabine
Monitoring & Follow-up
Monitor HIV-1 RNA levels to ensure maintenance of viral suppression
Observe for adverse events and tolerability over time
Assess adherence and potential drug interactions regularly
Risks
Potential loss of efficacy if co-administered with CYP3A inducers or lamivudine/emtricitabine
Risk of virologic failure if resistance to doravirine is present
Unknown long-term safety beyond 96 weeks
Patient & Prescribing Data
Adults with suppressed HIV-1 infection switching from baseline antiretroviral therapy
Approximately 92% achieved viral suppression at 48 weeks with DOR/ISL, comparable to 94% with standard therapy; low discontinuation rates and stable safety profile observed through 96 weeks
Clinical Best Practices
Confirm eligibility criteria including viral suppression and resistance profile before initiating DOR/ISL
Educate patients on adherence and potential drug interactions
Consider DOR/ISL for patients with comorbidities or those seeking reduced medication burden
Regularly monitor viral load and safety parameters during therapy
